Physician profile
Tomas Wharton
NPI 1003157017
$2,941.58
in general payments reported to CMS, 2019-2025
10 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 92% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $57.75 · 2021: $33.80 · 2022: $283 · 2023: $504 · 2024: $500 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,160.46 | 2022-2025 | Apretude, Dovato |
| Alkermes, INC. | $495.99 | 2023-2025 | Vivitrol, Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.71 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $292.81 | 2025 | Caplyta |
| Gilead Sciences, INC. | $259.48 | 2019-2025 | Biktarvy |
| Novartis Pharmaceuticals Corporation | $121.60 | 2019 | |
| Indivior INC. | $107.97 | 2024-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $58.86 | 2025 | Pifeltro, Capvaxive, Delstrigo |
| Orexo US, INC. | $51.58 | 2021-2024 | Zubsolv |
| Allergan, INC. | $17.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Wharton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.